May 26, 2022 11:24 AM EDT
Pharma
Law

Long­time Kad­mon con­sul­tant slapped with in­sid­er trad­ing charges re­lat­ed to $1.9B Sanofi buy­out

Nicole DeFeudis

Editor

Months af­ter Sanofi snapped up Kad­mon for $1.9 bil­lion, a long­time Kad­mon con­sul­tant has been ac­cused of us­ing in­sid­er knowl­edge of the buy­out to make …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times